Genocea Biosciences Inc (GNCA) Stock
GNCA is no longer traded. Genocea Biosciences was delisted from the Nasdaq in February 2023.
Prices on this page are historical; the last trade was February 24, 2023 at $0.00.
Genocea Biosciences stock price history
GNCA final trading statistics
- Final close
- $0.00
- Final trading day
- Feb 24, 2023
- Market cap at delisting
- $5.9K
- Shares outstanding
- 58.78M
- Final 52-week range
- $0.00 – $1.45
- Avg. volume (final 3 mo.)
- 46,862
- All-time high (split-adj.)
- $181.60 · Jun 2014
- All-time low (split-adj.)
- $0.00 · Dec 2022
- Return since IPO
- -100.0%
- Beta
- 1.60
- Book value / share
- $0.21
- Price / book
- 0.00
Genocea Biosciences annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $1.64M | -$33.2M | -$0.47 |
| FY2020 | $1.36M | -$43.7M | -$1.16 |
| FY2019 | $0.00 | -$39.0M | -$2.24 |
| FY2018 | $0.00 | -$27.8M | -$2.77 |
| FY2017 | $0.00 | -$56.7M | -$12.48 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Genocea Biosciences Inc
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Genocea Biosciences stock FAQ
What happened to Genocea Biosciences stock?
Genocea Biosciences stock was delisted from the Nasdaq. Its final close was $0.00 on February 24, 2023.
Is GNCA stock still trading?
No. GNCA was delisted from the Nasdaq in February 2023 and no longer trades on a U.S. exchange.
What was the last price of GNCA stock?
GNCA closed at $0.00 on its final trading day, February 24, 2023, for a market value of about $5.9K.
What were Genocea Biosciences's revenue and earnings in its last full fiscal year?
Genocea Biosciences reported revenue of $1.64M and net income of -$33.2M in fiscal 2021, its last full year as a public company.
When did Genocea Biosciences go public?
Genocea Biosciences Inc stock began trading on February 5, 2014.